



SOSEI ANNOUNCES SIGNIFICANT EXERCISE OF STOCK ACQUISITION RIGHTS

Tokyo, Japan – 1 March 2007: Sosei Group Corporation (“Sosei”, TSE Mothers Index: 4565) a biopharmaceutical company, today announces the exercise of a number of Stock Acquisition Rights (“SARs”) issued on 22 January 2007.

1. Name of Stock Acquisition Rights: Sosei Group Corporation,
Stock Acquisition Rights
(11th Series Stock Acquisition Rights)
2. Exercise date: 1 March 2007
3. Number of shares to be issued: 1,800 shares
New shares : 1,800 shares
Treasury stocks: 0 shares
4. Exercise price: 190,500 Yen
5. To be paid: 342,900,000 Yen
6. Number of unexercised Stock Acquisition Rights: 450 (Common Shares 8,100)

Enquiries

Sosei Group Corporation

Tokyo: Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan
Hiroki MAEKAWA, Representative Executive Officer,
E-mail: hmaekawa@sosei.com Tel: +81-3-5210-3399 Fax: +81-3-5210-3291

UK: John DAFFURN, SVP Corporate Development
E-mail: daffurnj@sosei.com Tel: +44 1799 532350 Fax: +44 1799 532351

Financial Dynamics Tel: + 44 (0)207 831 3113

Julia Phillips

The Trout Group Tel: +1 646 378 2900

Brandon Lewis
Thomas Fechtner

Notes for Editors:

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit www.sosei.com